Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations

E-ISSN： 1875-533x|18|18|2674-2685

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.18, 2011-06, pp. : 2674-2685

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 175-187

Bentham Science Publishers

Access to resources Recommend Favorite

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

Current Cancer Drug Targets, Vol. 8, Iss. 3, 2008-05 ,pp. : 187-198

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs

Current Pharmaceutical Design, Vol. 16, Iss. 12, 2010-04 ,pp. : 1410-1416

Bentham Science Publishers

Access to resources Recommend Favorite